Par Health Recalls Two Lots of Brevital Sodium Due to Particulate Matter
Par Health has issued a voluntary recall to the hospital level for two lots of Brevital Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP). The action was initiated due to the presence of particulate matter identified as cellulose. Administration of the affected product carries a risk of life-threatening adverse health outcomes, including pulmonary emboli, blood vessel occlusions leading to tissue death and organ damage, and vein inflammation.
The affected lots include Lot 86930 and Lot 88623, which were distributed nationwide in the United States. To date, the company has not received any reports of adverse events linked to this recall. Wholesalers and hospital pharmacies possessing the recalled batches are advised to immediately stop using and distributing the product and arrange for its return.
Key points
- Voluntary recall of two lots of Brevital Sodium 500 mg/vial CIV due to cellulose particulate matter.
- Affected lot numbers are 86930 and 88623.
- Risks include pulmonary emboli, vascular occlusions, and venous inflammation.
- No adverse events have been reported to date.
What it means for you
Clinicians and hospital pharmacists should immediately inspect their inventory, discontinue use of the recalled lots, and arrange for their return as instructed by the distributor. Healthcare professionals in Pakistan should verify local product registrations and check with the Drug Regulatory Authority of Pakistan (DRAP) for any related safety alerts or local availability updates.
Par Health Issues Voluntary Nationwide Recall of Two Lots of Brevital® Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP) Due to the Presence of Particulate Matter
Summarised automatically from the official announcement. For educational purposes only — check the original source before making clinical decisions.